While CC carriers show 2.55x greater odds of remission, the functional pathway linking this polymorphism to treatment efficacy is unknown. This mechanistic gap limits personalized treatment approaches and drug development targeting KCNK2. Gap type: unexplained_observation Source paper: Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment. (None, None, PMID:19741570)
Landscape Summary: How does KCNK2 rs6686529 genotype mechanistically influence antidepressant treatment response? is a 0.77 priority gap in neuropsychiatry. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
How does KCNK2 rs6686529 genotype mechanistically influence antidepressant treatment response? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: